<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02699866</url>
  </required_header>
  <id_info>
    <org_study_id>CR02/15</org_study_id>
    <nct_id>NCT02699866</nct_id>
  </id_info>
  <brief_title>Implant Survival After Insertion of Bone Level Tapered (BLT) Implant Ø 2.9 mm in the Clinical Practice Setting</brief_title>
  <official_title>A Multi-Center, Prospective, Single Cohort, Post-Market Clinical Follow-Up (PMCF) Study to Assess Implant Survival After Insertion of Straumann® Bone Level Tapered (BLT) Implant Ø 2.9 mm in the Clinical Practice Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Straumann AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Straumann AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Straumann Bone Level Tapered (BLT) implant Ø 2.9 mm implant was developed to allow&#xD;
      treatment of patients with single tooth gaps of small dimensions in the lateral and central&#xD;
      incisor positions in the mandible and in the lateral incisor positions in the maxilla. These&#xD;
      positions are reduced-load-bearing compared to more posterior positions.&#xD;
&#xD;
      During this study performance and safety of the Straumann BLT implants Ø 2.9 mm in the&#xD;
      clinical practice setting will be investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, prospective, single cohort, post-market clinical follow-up (PMCF)&#xD;
      study. The total study duration for each patient should be 12 ± 1 months.&#xD;
&#xD;
      Straumann BLT implants Ø 2.9 mm will be placed in central and lateral incisors in the&#xD;
      mandible and lateral incisors in the maxilla for single tooth replacement, followed by&#xD;
      provisional prosthetic loading after 6 ± 2 weeks and by final prosthetic loading 4 ± 1 months&#xD;
      after implant placements.&#xD;
&#xD;
      In total 7 visits per patient are scheduled in this study. Implant survival, PES, implant&#xD;
      success, bone level changes and adverse events (AEs) will be assessed.&#xD;
&#xD;
      The investigational device is a CE-(Conformité Européenne, meaning European Conformity)&#xD;
      marked product. Straumann BLT implants Ø 2.9 mm Roxolid SLActive (sand blasted, large grit,&#xD;
      acid etched surface) are available in lengths of 10, 12 and 14 mm.&#xD;
&#xD;
      Four centers in Germany will participate. The study and any amendments will be performed as&#xD;
      far as possible according to International Organization for Standardization (ISO) 14155 and&#xD;
      conform to the Declaration of Helsinki (last revision Fortaleza 2013) and local legal and&#xD;
      regulatory requirements.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">November 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Implant Survival Rate at 12 Months After Implant Placement</measure>
    <time_frame>12 months after implant placement</time_frame>
    <description>A &quot;surviving implant&quot; is an implant stably inserted in the subject's jaw bone at the time of assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pink Esthetic Score (PES) at 6 Months After Implant Placement</measure>
    <time_frame>6 months after implant placement</time_frame>
    <description>The Pink esthetic score allows an objective evaluation of peri-implant soft tissue of single tooth implants based on 7 variables and is highly reproducible. Each variable will be assessed using a 0-1-2 scoring system; 0 being the lowest, and 2 being the highest value. The minimum achievable PES is 0 and the maximum score is 14. The higher the value, the better the outcome.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Implant Success Rate at 12 Months After Implant Placement</measure>
    <time_frame>12 months after implant placement</time_frame>
    <description>A &quot;successful implant&quot; is an implant where all of the following success criteria (according to Buser et al., 1992) apply:&#xD;
Absence of persisting subjective discomfort such as pain, foreign body perception and/or dysesthesia (painful sensation);&#xD;
Absence of recurrent peri-implant infection with suppuration;&#xD;
Absence of tactile implant mobility;&#xD;
Absence of a continuous peri-implant radiolucency.</description>
  </other_outcome>
  <other_outcome>
    <measure>Marginal Bone Level Changes at 12 Months After Implant Placement</measure>
    <time_frame>Baseline and 12 months after implant placement</time_frame>
    <description>An independent expert is contracted to perform the bone level measurements from the X-rays. The vertical bone level is evaluated by measuring the distance from the implant shoulder to the first visible bone contact on the implant. Measurements are taken at the mesial and distal aspects of the implant, and an average value is calculated. Mean bone level changes are computed by subtracting the average bone level at 12 months after implant placement from the average bone level at baseline (implant placement). Hence, negative bone level changes are representing bone loss; vice versa positive changes representing bone gain. Measurements take into account distortion based on changes on the radiograph from the true dimension of the implant.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Adverse Events and Adverse Device Effects</measure>
    <time_frame>Screening, Baseline, 7-14 days after implant placement, 6 weeks after implant placement, 4 months after implant placement, 6 months after implant placement and 12 months after implant placement</time_frame>
    <description>At each visit the Investigator should determine if any adverse events occurred since the last study visit by speaking with the patient and reviewing any dental and medical records. These AEs, along with any AEs from the current study visit, should be documented and reported as described in Section 8 of the protocol. In addition the Investigator should evaluate the status of any ongoing AEs throughout the study.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Tooth Loss</condition>
  <arm_group>
    <arm_group_label>BLT Implant Ø 2.9 mm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Straumann BLT Implants Ø 2.9 mm are available with a length of 10, 12 and 14 mm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BLT Implant Ø 2.9 mm</intervention_name>
    <description>Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.</description>
    <arm_group_label>BLT Implant Ø 2.9 mm</arm_group_label>
    <other_name>Short Diameter Implant (SDI)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have voluntarily signed the Informed Consent Form before any study&#xD;
             related procedures are performed, are willing and able to attend scheduled follow-up&#xD;
             visits and agree that the pseudonymized data are collected and analyzed.&#xD;
&#xD;
          -  Patients must be males or females who are a minimum of 18 years of age.&#xD;
&#xD;
          -  Patients with a minimum of 4 weeks history of edentulism in the study area, minimal&#xD;
             interdental space and in need of a single tooth replacement with a dental implant&#xD;
             central and lateral incisors in the mandible and lateral incisors in the maxilla&#xD;
             (Federation Dentaire Internationale (FDI) positions 12, 22, 31, 32, 41 or 42).&#xD;
&#xD;
          -  Presence of natural tooth or implants adjacent to the study implant position (single&#xD;
             tooth gap).&#xD;
&#xD;
          -  Patients with complete soft tissue coverage of the socket at implant placement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with inadequate bone volume and / or quality or metabolic bone disorder.&#xD;
&#xD;
          -  Patients with local root remnants.&#xD;
&#xD;
          -  Patients with inadequate wound healing capacity.&#xD;
&#xD;
          -  Patients with not completed maxillary and mandibular growth.&#xD;
&#xD;
          -  Patients with serious internal medical problems, uncontrolled bleeding disorders,&#xD;
             psychoses, prolonged therapy-resistant functional disorders, xerostomia, weakened&#xD;
             immune system, illnesses requiring periodic use of steroids or uncontrollable&#xD;
             endocrine disorders.&#xD;
&#xD;
          -  Patients with poor general state of health.&#xD;
&#xD;
          -  Patients with drug or alcohol abuse.&#xD;
&#xD;
          -  Patients with allergies or hypersensitivity to chemical ingredients of&#xD;
             titanium-zirconium alloy.&#xD;
&#xD;
          -  Patients with conditions or circumstances, in the opinion of the Investigator, which&#xD;
             would prevent completion of study participation or interfere with analysis of study&#xD;
             results, such as history of non-compliance or unreliability.&#xD;
&#xD;
          -  A woman who is pregnant or planning to become pregnant at any point during the study&#xD;
             duration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keyvan Sagheb, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Klinik für Mund-Kiefer-Gesichtschirurgie, Plastische Operationen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kieferchirurgische Gemeinschaftspraxis Dr. Dr. Stroink &amp; Kollegen</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40210</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medi+</name>
      <address>
        <city>Mainz</city>
        <zip>55128</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Klinik für Mund-Kiefer-Gesichtschirurgie, Plastische Operationen</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Klinik für Mund-, Kiefer- und Gesichtschirurgie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kieferchirurgische Praxen Hentschel &amp; Herrmann</name>
      <address>
        <city>Zwickau</city>
        <zip>08056</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.mah.se/CAPP/Methods-and-Indices/Oral-Hygiene-Indices/Silness-Loe-Index/.</url>
    <description>Silness J, Loe H. 196, available at</description>
  </link>
  <reference>
    <citation>Steinemann SG. Titanium--the material of choice? Periodontol 2000. 1998 Jun;17:7-21. Review.</citation>
    <PMID>10337309</PMID>
  </reference>
  <reference>
    <citation>Gottlow J, Dard M, Kjellson F, Obrecht M, Sennerby L. Evaluation of a new titanium-zirconium dental implant: a biomechanical and histological comparative study in the mini pig. Clin Implant Dent Relat Res. 2012 Aug;14(4):538-45. doi: 10.1111/j.1708-8208.2010.00289.x. Epub 2010 Jun 25.</citation>
    <PMID>20586785</PMID>
  </reference>
  <reference>
    <citation>Kobayashi E, Matsumoto S, Doi H, Yoneyama T, Hamanaka H. Mechanical properties of the binary titanium-zirconium alloys and their potential for biomedical materials. J Biomed Mater Res. 1995 Aug;29(8):943-50.</citation>
    <PMID>7593037</PMID>
  </reference>
  <reference>
    <citation>Al-Nawas B, Brägger U, Meijer HJ, Naert I, Persson R, Perucchi A, Quirynen M, Raghoebar GM, Reichert TE, Romeo E, Santing HJ, Schimmel M, Storelli S, ten Bruggenkate C, Vandekerckhove B, Wagner W, Wismeijer D, Müller F. A double-blind randomized controlled trial (RCT) of Titanium-13Zirconium versus Titanium Grade IV small-diameter bone level implants in edentulous mandibles--results from a 1-year observation period. Clin Implant Dent Relat Res. 2012 Dec;14(6):896-904. doi: 10.1111/j.1708-8208.2010.00324.x. Epub 2011 Mar 17.</citation>
    <PMID>21414131</PMID>
  </reference>
  <reference>
    <citation>Benic GI, Gallucci GO, Mokti M, Hämmerle CH, Weber HP, Jung RE. Titanium-zirconium narrow-diameter versus titanium regular-diameter implants for anterior and premolar single crowns: 1-year results of a randomized controlled clinical study. J Clin Periodontol. 2013 Nov;40(11):1052-61. doi: 10.1111/jcpe.12156. Epub 2013 Sep 8.</citation>
    <PMID>24015975</PMID>
  </reference>
  <reference>
    <citation>Al-Nawas B, Domagala P, Fragola G, Freiberger P, Ortiz-Vigón A, Rousseau P, Tondela J. A Prospective Noninterventional Study to Evaluate Survival and Success of Reduced Diameter Implants Made From Titanium-Zirconium Alloy. J Oral Implantol. 2015 Aug;41(4):e118-25. doi: 10.1563/AAID-JOI-D-13-00149. Epub 2014 Mar 25.</citation>
    <PMID>24666383</PMID>
  </reference>
  <reference>
    <citation>Quirynen M, Al-Nawas B, Meijer HJ, Razavi A, Reichert TE, Schimmel M, Storelli S, Romeo E; Roxolid Study Group. Small-diameter titanium Grade IV and titanium-zirconium implants in edentulous mandibles: three-year results from a double-blind, randomized controlled trial. Clin Oral Implants Res. 2015 Jul;26(7):831-40. doi: 10.1111/clr.12367. Epub 2014 Apr 9.</citation>
    <PMID>24713048</PMID>
  </reference>
  <reference>
    <citation>Klein MO, Schiegnitz E, Al-Nawas B. Systematic review on success of narrow-diameter dental implants. Int J Oral Maxillofac Implants. 2014;29 Suppl:43-54. doi: 10.11607/jomi.2014suppl.g1.3. Review.</citation>
    <PMID>24660189</PMID>
  </reference>
  <reference>
    <citation>Hämmerle CH, Chen ST, Wilson TG Jr. Consensus statements and recommended clinical procedures regarding the placement of implants in extraction sockets. Int J Oral Maxillofac Implants. 2004;19 Suppl:26-8. Review.</citation>
    <PMID>15635943</PMID>
  </reference>
  <reference>
    <citation>Mombelli A, van Oosten MA, Schurch E Jr, Land NP. The microbiota associated with successful or failing osseointegrated titanium implants. Oral Microbiol Immunol. 1987 Dec;2(4):145-51.</citation>
    <PMID>3507627</PMID>
  </reference>
  <reference>
    <citation>Buser D, Martin W, Belser UC. Optimizing esthetics for implant restorations in the anterior maxilla: anatomic and surgical considerations. Int J Oral Maxillofac Implants. 2004;19 Suppl:43-61. Review.</citation>
    <PMID>15635945</PMID>
  </reference>
  <reference>
    <citation>Fürhauser R, Florescu D, Benesch T, Haas R, Mailath G, Watzek G. Evaluation of soft tissue around single-tooth implant crowns: the pink esthetic score. Clin Oral Implants Res. 2005 Dec;16(6):639-44.</citation>
    <PMID>16307569</PMID>
  </reference>
  <reference>
    <citation>Laurell L, Lundgren D. Marginal bone level changes at dental implants after 5 years in function: a meta-analysis. Clin Implant Dent Relat Res. 2011 Mar;13(1):19-28. doi: 10.1111/j.1708-8208.2009.00182.x. Review.</citation>
    <PMID>19681932</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 1, 2016</study_first_submitted>
  <study_first_submitted_qc>March 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2016</study_first_posted>
  <results_first_submitted>August 25, 2020</results_first_submitted>
  <results_first_submitted_qc>August 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2020</results_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Small diameter implant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tooth Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 9, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT02699866/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First site was initiated on 11th DEC 2015 (Mainz University). The first patient was included on 12 FEB 2016 and the last patient out was on 07 JUN 2019 (last 1-year follow-up). The last centre was closed on 10 DEC 2019 (Münster).</recruitment_details>
      <pre_assignment_details>This was a non-randomized study (N/A).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BLT Implant Ø 2.9 mm</title>
          <description>The Straumann BLT Implants Ø 2.9 mm are available with a length of 10, 12 and 14 mm.&#xD;
BLT Implant Ø 2.9 mm: Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46">First study centre initiation.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Included</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38">Last study centre close-out.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BLT Implant Ø 2.9 mm</title>
          <description>The Straumann BLT Implants Ø 2.9 mm are available with a length of 10, 12 and 14 mm.&#xD;
BLT Implant Ø 2.9 mm: Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.53" spread="18.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Implant Survival Rate at 12 Months After Implant Placement</title>
        <description>A &quot;surviving implant&quot; is an implant stably inserted in the subject's jaw bone at the time of assessment.</description>
        <time_frame>12 months after implant placement</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BLT Implant Ø 2.9 mm</title>
            <description>The Straumann BLT Implants Ø 2.9 mm are available with a length of 10, 12 and 14 mm.&#xD;
BLT Implant Ø 2.9 mm: Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Survival Rate at 12 Months After Implant Placement</title>
          <description>A &quot;surviving implant&quot; is an implant stably inserted in the subject's jaw bone at the time of assessment.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.68" lower_limit="79.00" upper_limit="97.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pink Esthetic Score (PES) at 6 Months After Implant Placement</title>
        <description>The Pink esthetic score allows an objective evaluation of peri-implant soft tissue of single tooth implants based on 7 variables and is highly reproducible. Each variable will be assessed using a 0-1-2 scoring system; 0 being the lowest, and 2 being the highest value. The minimum achievable PES is 0 and the maximum score is 14. The higher the value, the better the outcome.</description>
        <time_frame>6 months after implant placement</time_frame>
        <population>11 missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>BLT Implant Ø 2.9 mm</title>
            <description>The Straumann BLT Implants Ø 2.9 mm are available with a length of 10, 12 and 14 mm.&#xD;
BLT Implant Ø 2.9 mm: Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.</description>
          </group>
        </group_list>
        <measure>
          <title>Pink Esthetic Score (PES) at 6 Months After Implant Placement</title>
          <description>The Pink esthetic score allows an objective evaluation of peri-implant soft tissue of single tooth implants based on 7 variables and is highly reproducible. Each variable will be assessed using a 0-1-2 scoring system; 0 being the lowest, and 2 being the highest value. The minimum achievable PES is 0 and the maximum score is 14. The higher the value, the better the outcome.</description>
          <population>11 missing values.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="10.5" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Implant Success Rate at 12 Months After Implant Placement</title>
        <description>A &quot;successful implant&quot; is an implant where all of the following success criteria (according to Buser et al., 1992) apply:&#xD;
Absence of persisting subjective discomfort such as pain, foreign body perception and/or dysesthesia (painful sensation);&#xD;
Absence of recurrent peri-implant infection with suppuration;&#xD;
Absence of tactile implant mobility;&#xD;
Absence of a continuous peri-implant radiolucency.</description>
        <time_frame>12 months after implant placement</time_frame>
        <population>2 missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>BLT Implant Ø 2.9 mm</title>
            <description>The Straumann BLT Implants Ø 2.9 mm are available with a length of 10, 12 and 14 mm.&#xD;
BLT Implant Ø 2.9 mm: Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Success Rate at 12 Months After Implant Placement</title>
          <description>A &quot;successful implant&quot; is an implant where all of the following success criteria (according to Buser et al., 1992) apply:&#xD;
Absence of persisting subjective discomfort such as pain, foreign body perception and/or dysesthesia (painful sensation);&#xD;
Absence of recurrent peri-implant infection with suppuration;&#xD;
Absence of tactile implant mobility;&#xD;
Absence of a continuous peri-implant radiolucency.</description>
          <population>2 missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7" lower_limit="75.8" upper_limit="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Marginal Bone Level Changes at 12 Months After Implant Placement</title>
        <description>An independent expert is contracted to perform the bone level measurements from the X-rays. The vertical bone level is evaluated by measuring the distance from the implant shoulder to the first visible bone contact on the implant. Measurements are taken at the mesial and distal aspects of the implant, and an average value is calculated. Mean bone level changes are computed by subtracting the average bone level at 12 months after implant placement from the average bone level at baseline (implant placement). Hence, negative bone level changes are representing bone loss; vice versa positive changes representing bone gain. Measurements take into account distortion based on changes on the radiograph from the true dimension of the implant.</description>
        <time_frame>Baseline and 12 months after implant placement</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BLT Implant Ø 2.9 mm</title>
            <description>The Straumann BLT Implants Ø 2.9 mm are available with a length of 10, 12 and 14 mm.&#xD;
BLT Implant Ø 2.9 mm: Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.</description>
          </group>
        </group_list>
        <measure>
          <title>Marginal Bone Level Changes at 12 Months After Implant Placement</title>
          <description>An independent expert is contracted to perform the bone level measurements from the X-rays. The vertical bone level is evaluated by measuring the distance from the implant shoulder to the first visible bone contact on the implant. Measurements are taken at the mesial and distal aspects of the implant, and an average value is calculated. Mean bone level changes are computed by subtracting the average bone level at 12 months after implant placement from the average bone level at baseline (implant placement). Hence, negative bone level changes are representing bone loss; vice versa positive changes representing bone gain. Measurements take into account distortion based on changes on the radiograph from the true dimension of the implant.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-0.4" upper_limit="-0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence of Adverse Events and Adverse Device Effects</title>
        <description>At each visit the Investigator should determine if any adverse events occurred since the last study visit by speaking with the patient and reviewing any dental and medical records. These AEs, along with any AEs from the current study visit, should be documented and reported as described in Section 8 of the protocol. In addition the Investigator should evaluate the status of any ongoing AEs throughout the study.</description>
        <time_frame>Screening, Baseline, 7-14 days after implant placement, 6 weeks after implant placement, 4 months after implant placement, 6 months after implant placement and 12 months after implant placement</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BLT Implant Ø 2.9 mm</title>
            <description>The Straumann BLT Implants Ø 2.9 mm are available with a length of 10, 12 and 14 mm.&#xD;
BLT Implant Ø 2.9 mm: Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events and Adverse Device Effects</title>
          <description>At each visit the Investigator should determine if any adverse events occurred since the last study visit by speaking with the patient and reviewing any dental and medical records. These AEs, along with any AEs from the current study visit, should be documented and reported as described in Section 8 of the protocol. In addition the Investigator should evaluate the status of any ongoing AEs throughout the study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Adverse Events (AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adverse Device Effects (ADE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Serious Adverse Events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Serious Adverse Device Effects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unanticipated Serious Adv. Device Effect (USADE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No AEs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Adverse Events were recorded at every patient visit and monitored during IMV. Safety Board meetings were conducted to assess the reported and monitored AEs from a Sponsor-Perspective.</desc>
      <group_list>
        <group group_id="E1">
          <title>BLT Implant Ø 2.9 mm</title>
          <description>The Straumann BLT Implants Ø 2.9 mm are available with a length of 10, 12 and 14 mm.&#xD;
BLT Implant Ø 2.9 mm: Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>ISO14155</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Common cold</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Implant lost</sub_title>
                <description>Implant lost on pos. 22, subject discontinued.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael McCaskey, Team Leader Clinical Research</name_or_title>
      <organization>Institut Straumann AG</organization>
      <phone>+41619651741</phone>
      <email>michael.mccaskey@straumann.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

